• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials
abstracts & posters

Outcome of severe vaso occlusive crisis in sickle cell disease adults admitted to referral centers in Africa and Europe. Preliminary results from the presev 2 study

key information

source: American Society of Hematology

year: 2017

authors: Dapa Diallo, Mehdi Khellaf, Gonzalo De Luna, Sandrine Dautheville, Louis Affo, Stephanie Ngo, Tatiana besse-Hammer, Yvon Segbena, jean Benoit Arlet, François Lionnet, Sylvain le-Jeune, Anoosha Habibi, Bertrand Godeau, Frédéric Galactéros, Pablo Bartolucci


Introduction: Vaso-Occlusive Crisis (VOC), the most common manifestation of sickle cell disease (SCD), is the first cause of death, particularly when complicated by an acute chest syndrome (ACS). In the PRESEV1 study, we developed a predictive score of secondary ACS in SCD patient admitted in the hospital for VOC (AUC = 0.840 [95% CI: 0.780 – 0.900]), with a negative predictive value of 98.8% for the low level risk and a positive predictive value of 39.5%. The aim of the PRESEV-2 study is to validate the predictive score of ACS on adults and children with SCD in Europe and Africa. Herein we present preliminary data on 235 adults with a severe VOC included in 11 referral centers from 4 countries.

Patients and Methods: We conduct an international multicenter prospective observational study. The primary outcome measure is the occurrence of an ACS. The ACS is defined as a new auscultatory abnormality (crepitation or bronchial breathing) OR the association of a new radiologic infiltrate AND chest pain or decreased breath sounds. Secondary outcome measures are length of hospitalization, transfusion, morphine consumption, mortality and hospitalization in intensive care unit. Inclusion criteria are: SS or S-b0 thalassemia patients, VOC admitted at the emergency unit (VOC is defined as pain or tenderness affecting at least one part of the body not attributable to other causes) that required hospitalization and opioids (level 3). Exclusion criteria are: no inaugural ACS, homeless patients, pregnancy, deprived of their liberty or under guardianship, unable to understand the purpose and conditions of carrying out the study, unable to give consent.

Results: From march 2016 to june 2017, 112 adult patients were included in Africa and 122 adults in Europe. Patients in Africa were younger than in Europe with a mean age, respectively, of 26 ± 7 yrs and 29 ± 8 yrs (p=0.008). Sex ratio (M/F) in Africa was 0.84 and 0.95 in Europe. Use of hydroxyurea was significantly higher in Europe (65%) than in Africa (6%) (p<0.0001). The ACS incidence was significantly higher in Africa than in Europe, respectively 22% and 11% (OR=2.24; p=0.03), in both areas the time for ACS appearance was the second day. Transfusion was performed in 27% in Africa and 6% in Europe (p<0.001), ACS was the main cause of transfusion (53.3% in Africa and 62.5% in Europe). Patients with ACS were more transfused in Africa than in Europe, respectively 64% and 35.7% but the difference was not significant. Mortality was 3.6% in Africa and was not observed in Europe; circumstances of death were stroke (1), profound anemia (1), kidney failure (1) and VOC (1).

organization: Centre de Recherche et de Lutte contre la Drépanocytose, Bamako, Mali; University of Bamako Mali, Bamako, Mali; Henri Mondor Hospital, Creteil, FRA; APHP Hôpital Georges Pompidou, Paris, France; APHP Hopital Tenon, Paris, France; APHP Louis Mourier, Colombes, France; CHU Rouen, Rouen, France; CHU Brugmann, Bruxelles, Belgium; Hôpital universitaire de Lome Campus, Lome, Togo; APHP Hôpital Européen Georges Pompidou, paris, France; APHP. Hôpital Tenon, Paris, France; APHP CHU Avicenne, Bobigny, France; Hopital Henri Mondor - APHP, Creteil Cedex, FRA; IMRB UPEC, Créteil, France

read more

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.